AbbVie
ABBV
3,172 hedge funds and large institutions have $198B invested in AbbVie in 2022 Q4 according to their latest regulatory filings, with 365 funds opening new positions, 1,196 increasing their positions, 1,261 reducing their positions, and 100 closing their positions.
265% more first-time investments, than exits
New positions opened: 365 | Existing positions closed: 100
25% more funds holding in top 10
Funds holding in top 10: 278 → 348 (+70)
21% more capital invested
Capital invested by funds: $164B → $198B (+$34.1B)
7% more funds holding
Funds holding: 2,972 → 3,172 (+200)
0.42% more ownership
Funds ownership: 68.98% → 69.4% (+0.42%)
4% less call options, than puts
Call options by funds: $2.99B | Put options by funds: $3.13B
5% less repeat investments, than reductions
Existing positions increased: 1,196 | Existing positions reduced: 1,261
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$881M |
| 2 |
Morgan Stanley
New York
|
+$734M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$503M |
| 4 |
JP Morgan Chase
New York
|
+$373M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$352M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$628M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$432M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$186M |
| 4 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$176M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$171M |
ABBV Hedge Fund Activity: Q4 2022 in Review
3,172 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2022, worth a combined $198B — up 21% from $164B a quarter earlier.
Buyers outnumbered sellers: 365 funds opened new ABBV positions and 100 closed out — a net gain of 265 holders — while 1,196 added to existing stakes and 1,261 trimmed.
The largest buyer was BlackRock, adding an estimated $881M. The largest seller was T. Rowe Price Associates, cutting an estimated $628M.
- 3,172 institutional investors held AbbVie (ABBV) as of Q4 2022, up from 2,972 in Q3 2022.
- Funds reported $198B of AbbVie stock for Q4 2022, up 21% quarter-over-quarter.
- 365 funds opened new AbbVie positions in Q4 2022 and 100 closed out, a net change of +265 holders.
- The largest AbbVie buyer in Q4 2022 was BlackRock, an estimated $881M added.
- The largest AbbVie seller in Q4 2022 was T. Rowe Price Associates, an estimated $628M sold.
Based on aggregated 13F filings for Q4 2022.